Business Context and Reporting Period
Company: MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: MIRA is a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, metabolic, and addiction-related disorders. The company operates as a single segment and is classified as an Emerging Growth Company and a Smaller Reporting Company.
Pipeline Highlights:
- Ketamir-2: An oral NMDA receptor modulator for neuropathic pain. Completed Phase 1 clinical trial in healthy volunteers (SAD and MAD cohorts) with no serious adverse events reported. Planning Phase 2a trial in chemotherapy-induced peripheral neuropathy (CIPN) in H1 2026.
- MIRA-55: A non-psychoactive cannabinoid analog for inflammatory pain and CNS conditions. Currently in preclinical development; targeting IND submission subject to capital availability.
- SKNY-1: Acquired via merger with SKNY Pharmaceuticals, Inc. on September 29, 2025. A preclinical oral therapeutic targeting obesity and nicotine dependence via CB1, CB2, and MAO-B modulation. Targeting IND submission in 2026.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Net Loss | $(10,442) | $(7,853) |
| Net Loss Attributable to Common Stockholders | $(31,999) | $(7,853) |
| Loss Per Share (Basic & Diluted) | $(1.35) | $(0.51) |
| Operating Expenses (Total) | $10,493 | $8,018 |
| Research & Development Expenses | $1,720 | $3,306 |
| General & Administrative Expenses | $8,773 | $4,713 |
| Cash Used in Operating Activities | $(4,662) | $(5,561) |
| Cash Provided by Financing Activities | $8,176 | $3,791 |
| Cash and Cash Equivalents (Ending) | $6,347 | $2,833 |
| Accumulated Deficit | $(39,580) | $(29,138) |
Note: The significant increase in Net Loss Attributable to Common Stockholders in 2025 includes a non-cash "deemed dividend" charge of $21.6 million related to the SKNY acquisition.
Material Changes vs. Prior Period
- Acquisition of SKNY Pharmaceuticals: On September 29, 2025, MIRA completed a stock-for-stock merger with SKNY Pharmaceuticals, Inc. MIRA issued 19.8 million shares valued at $26.3 million. The net assets acquired were valued at $4.7 million, resulting in a $21.6 million deemed dividend charge to Additional Paid-In Capital, significantly impacting the Net Loss attributable to common stockholders.
- Operating Expenses: General and Administrative (G&A) expenses increased by $4.1 million (86%) year-over-year, primarily driven by a $6.3 million increase in stock-based compensation. Research and Development (R&D) expenses decreased by $1.6 million (48%) due to reduced development costs for MIRA-55.
- Liquidity: Cash and cash equivalents increased by $3.5 million to $6.3 million, supported by $8.2 million in financing activities, including $6.7 million from At-The-Market (ATM) offerings and proceeds from option exercises.
- Capital Structure: Shares outstanding increased from 16.6 million (2024) to 41.9 million (2025) due to the SKNY acquisition and ATM sales.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects cash and cash equivalents to fund operations into at least the first quarter of 2027. However, the company explicitly states it does not have sufficient cash to support operations for the 12 months following the issuance of the financial statements without additional funding. The company plans to secure capital through public/private equity offerings, strategic alliances, or collaborations.
Going Concern Warning
The independent auditor's report includes an explanatory paragraph regarding "substantial doubt" about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit of $39.6 million. The financial statements do not include adjustments that might result from the outcome of this uncertainty.
Key Risks
- Regulatory Approval: High risk of failure in clinical trials; no products are currently approved for sale.
- Liquidity: Dependence on future financing to continue operations; failure to raise capital could force curtailment of development.
- Intellectual Property: Reliance on licenses from related parties (MIRALOGX); MIRA-55 currently has no issued patents.
- Related Party Transactions: Significant relationships with MIRALOGX and Bay Shore Trust, including licensing agreements and financing.
Unusual Items
- Deemed Dividend: A $21.6 million non-cash charge recorded in 2025 due to the excess fair value of shares issued in the SKNY acquisition over the net assets received.
- Executive Compensation: Significant stock-based compensation awards ($6.3 million in 2025) and milestone bonuses paid to the CEO upon achieving Phase 1 trial completion and market capitalization thresholds.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise additional capital to bridge the gap between current cash ($6.3M) and the 12-month going concern requirement.
- SKNY Acquisition Terms: Review the specific terms of the SKNY merger and the valuation of the $21.6 million deemed dividend to understand the dilution impact on existing shareholders.
- Related Party Conflicts: Assess the terms of the licensing agreements with MIRALOGX (8% royalty) and the potential conflicts of interest given the shared ownership with Bay Shore Trust.
- Clinical Trial Data: Await the final unblinded data from the Ketamir-2 Phase 1 trial to confirm safety and pharmacokinetic profiles before the Phase 2a initiation.
- Patent Status: Confirm the status of patent applications for MIRA-55, as the filing notes a lack of issued patents for this candidate.